stockrow
Friday 6 November 2026
Export PSNL’s income statement to Excel — free account
Personalis, Inc.
PSNL Healthcare Diagnostics & Research
Personalis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.6 million, down 17.7% from fiscal 2024.
- Revenue
- +76.6%
- EPS
- −33.3%
- Free cash flow
- −15.5%
Quarter to September 2026, against a year earlier
15.81
0.26
+1.67%
Follow PSNL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 3 | 3 | 3 |
| (35.02%) | (41.35%) | (50.32%) | (62.14%) | ||
| (26.89%) | (31.92%) | (37.55%) | (44.66%) | ||
ROIC |
(259.21%) | (297.38%) | (317.48%) | (358.37%) | |
Return on Tangible Assets |
(29.75%) | (35.71%) | (43.35%) | (53.25%) | |
Average Days of Receivables |
84.91 | 73.67 | 79.12 | 81.50 | |
Free Cash Flow per Share |
(0.89) | (0.81) | (0.96) | (0.91) | |
Free Cash Flow |
(79.45) | (84.53) | (100.85) | (97.57) | |
Capital Expenditures |
(4.50) | (5.06) | (8.56) | — | |
| Other line items | |||||
Cash ROIC |
(15.85%) | (17.32%) | (22.52%) | (24.19%) | |
Accounts Receivable Turnover |
5.72 | 5.38 | 5.56 | 4.98 | |
Accounts Payable Turnover |
5.56 | 5.41 | 4.69 | 5.25 | |
Inventory Turnover |
8.92 | 9.39 | 8.07 | 11.18 | |
Average Days of Payables |
88.01 | 83.12 | 96.03 | 78.60 | |
Days of Inventory on Hand |
41.63 | 45.44 | 57.83 | 40.06 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
72.17% | 80.85% | 80.55% | 74.31% | |
Selling, General and Administrative Expense of Revenue |
76.92% | 91.78% | 96.21% | 99.06% | |
Share Based Compensation of Revenue |
13.54% | 15.13% | 15.67% | 15.78% | |
Interest Coverage |
(429.55) | (457.69) | (536.66) | (683.98) | |
Operating CF/Net income |
0.92 | 0.83 | 0.86 | 0.82 | |
Depreciation/Fixed assets |
0.14 | 0.12 | 0.12 | 0.00 | |
Capex/Depreciation |
(0.74) | (0.87) | (1.49) | — | |
Revenue per Share |
0.78 | 0.62 | 0.66 | 0.75 | |
Operating CF per Share |
(0.84) | (0.76) | (0.88) | (0.91) | |
Capex per Share |
(0.05) | (0.05) | (0.08) | 0.00 | |
Capex to Sales |
0.06 | 0.08 | 0.12 | 0.00 |
Columns are period end dates · fundamentals updated 4 Nov 2026